Swiss Biotech Report 2006

INDEX 05USEFUL ADDRESSES ON BIOTECHNOLOGY IN SWITZERLAND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 02PREFACE / by Joseph Deiss, Minister of Economic Affairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 03A PRIME BUSINESS LOCATION FOR LIFE SCIENCE COMPANIES / by Location Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 06INDUSTRY STATEMENTS Interviews with Ernesto Bertarelli (CEO Serono), Alice Huxley (CEO Speedel), Urs Tuor (CEO GlycoVaxyn) . . . . . . . . . . . . 08WHAT KEEPS SWISS BIOTECHNOLOGY GOING? / by Oreste Ghisalba, CTI, the Swiss Innovation Promotion Agency . . . . . . . . . . . . . . .10AN EXPONENTIAL INCREASE IN STRENGTH / Company portrait: Santhera, Liestal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .12JOINING FORCES AND CONCENTRATING STRENGTHS / by Daniel Gygax, Swiss Biotechnet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13PARTIAL REVISION OF SWISS PATENT LAW / by Heinz Müller, Swiss Federal Institute of Intellectual Property . . . . . . . . . . . . . . . . . . . . . . . . . .16BIOTECH PROJECTS ATTRACT THE LION’S SHARE OF VENTURE CAPITAL / by Maurice Pedergnana, SECA . . . . . . . . . . . . . . . . 18LICENSED FOR SUCCESS / Company portrait: Helsinn, Lugano . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20ONE NATION ONE BIOTECH CLUSTER / by Domenico Alexakis, Swiss Biotech Association . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21CONDITIONS FOR RAISING CAPITAL HAVE GOTTEN BETTER / SWX round-table discussion with financial experts . . . . . . . . . . . . . . . 23SWISS BIOTECH INDUSTRY ON THE MOVE IN 2005 / by Jürg Zürcher and Markus Blaser, Ernst & Young . . . . . . . . . . . . . . . . . . . . . . . . . 26COMPETITION FOR ANTIBODIES / Company portrait: Molecular Partners, Zurich . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28POWERFUL PARTNERSHIPS / Benefits for big pharma and for biotech companies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29PROGRAMMED DEATH FOR TUMOUR CELLS / Company portrait: Apoxis, Lausanne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30MILESTONES IN MODERN BIOTECHNOLOGY / Timeline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31APPENDIX / Swiss Biotech Survey by Ernst & Young and the Swiss Federal Institute of Intellectual Property . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32